Loading clinical trials...
Loading clinical trials...
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AbbVie
NCT02219490 · Chronic Hepatitis C Virus (HCV) Infection Genotype 1
NCT02167945 · Chronic Hepatitis C Virus (HCV) Infection Genotype 1
NCT02640482 · Chronic Hepatitis C Virus (HCV) Infection
NCT02707952 · Chronic Hepatitis C Virus, Hepatitis C Virus
NCT01080222 · Chronic Hepatitis C Virus Infection
Aichi Medical University Hosp /ID# 152220
Nagakute, Aichi-ken
Nagoya City University Hospital /ID# 153642
Nagoya, Aichi-ken
Japanese Red Cross Narita Hosp /ID# 155894
Narita-shi, Chiba
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions